Pharmaceutical imports to the US surged in March as drugmakers stocked up ahead of potential tariffs on their products, which ...

Unlike other companies grappling with evolving trade policy, Pfizer didn't revise its full-year outlook Tuesday.

Some of the gains have come as the broader market has rallied, but there are signs fundamental factors are at play as well.

Diane Brady talks to Pfizer CEO Albert Bourla about defending science amid a backdrop of political threats. The big story: ...

CEO Albert Bourla is waiting for the US government to finalize its decision on whether to place a 25% tariff on ...

The company’s CEO said he’s had “productive discussions” with Trump administration officials on a recently launched trade ...

President Donald Trump on Monday signed an executive order to incentivize drug manufacturing in the U.S., streamlining the ...

Goldman Sachs keeps Neutral on Pfizer, citing unclear product growth plans and focus on M&A amid changing market valuations ...

Nevertheless, Albert Bourla has been lobbying the U.S. government—as high as President Donald Trump himself—to skip the ...

For years, Pfizer was the only drugmaker with treatments for the disease, called ATTR-CM, but BridgeBio’s CEO said in an ...

Pfizer’s R&D organization has been in flux for almost two years now, since the $43 billion acquisition of ADC specialist ...

Here's a list of the companies that have announced new U.S. investments since Trump took office: Merck on Tuesday said it is ...